Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;24(10):876-888.
doi: 10.1111/cns.13035. Epub 2018 Jul 29.

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

Aida Adlimoghaddam  1   2 , Melanie Neuendorff  3 , Banibrata Roy  4   5 , Benedict C Albensi  1   2
Affiliations
Review

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

Aida Adlimoghaddam et al. CNS Neurosci Ther. 2018 Oct.

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45 million people worldwide. Patients with severe AD require help with daily activities and show severe memory impairment. Currently, donepezil is one of two drugs approved by FDA and Health Canada for the treatment of severe AD (MMSE score <10). It is prescribed as 5 or 10 mg/d and an FDA-approved 23-mg/d dose.

Method: This review will discuss risks and benefits of donepezil at these doses in severe AD. Articles were identified using PubMed using the MeSH terms "donepezil" AND "Alzheimer Disease" AND "severe." Three double-blind, placebo-controlled, randomized studies, one post hoc analysis, and one subgroup analysis were selected.

Results: Donepezil was found to benefit patients in cognition and global functioning. The most consistent improvement was in severe impairment battery (SIB) scores. However, more patients treated with high dosage of donepezil discontinued their treatment due to various adverse events (AEs).

Conclusion: Clinicians must weigh benefits against adverse events when determining the course of therapy, as recommendations for cholinesterase inhibitors in advanced AD remain unclear and vary with different guidelines.

Keywords: Alzheiemr's disease; cognition; dementia; donepezil; dose; severity; treatment considerations.

PubMed Disclaimer

References

    1. Fratiglioni L, De Ronchi D, Aguero‐Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15(5):365‐375. - PubMed
    1. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population‐based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S10‐S15. - PubMed
    1. Aarsland D, Rongve A, Nore SP, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26(5):445‐452. - PubMed
    1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112‐2117. - PMC - PubMed
    1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer Disease I . The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1‐11.e3 - PubMed

Publication types

MeSH terms